Reviewing Harrow (NASDAQ:HROW) & Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Harrow (NASDAQ:HROW) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Harrow and Eyepoint Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1	2	7	0	2.60
Eyepoint Pharmaceuticals	1	6	4	0	2.27

Harrow currently has a consensus target price of $66.17, suggesting a potential upside of 116.80%. Eyepoint Pharmaceuticals has a consensus target price of $25.70, suggesting a potential upside of 642.77%. Given Eyepoint Pharmaceuticals’ higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Harrow.

Insider and Institutional Ownership

72.8% of Harrow shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Harrow and Eyepoint Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30 million	4.20	-$5.14 million	($1.00)	-30.52
Eyepoint Pharmaceuticals	$31.37 million	9.51	-$231.96 million	($3.74)	-0.93

Harrow has higher revenue and earnings than Eyepoint Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Harrow has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.

Profitability

This table compares Harrow and Eyepoint Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%

Summary

Harrow beats Eyepoint Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.